Skip to main content

Advertisement

Table 4 Neutralizing antibody-based immunogenicity with 95% CI in the per-protocol immunogenicity cohort

From: Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults

  Month 6 6 + 21 days 12 12 + 21 24 36 36 + 21 48
Titre ≥1:28 n/N; % (95% CI) Booster at Month 6
Primary strain 162/163; 99.4 163/163; 100 75/75; 100 74/75; 98.7 71/75; 94.7 73/75; 97.3
(96.6, 100) (97.8, 100) (95.2, 100)   (92.8, 100) (86.9, 98.5)   (90.7, 99.7)
Booster strain 160/162; 98.8 162/162; 100 74/74; 100 70/74; 94.6 66/75; 88.0 67/75; 89.3
(95.6, 99.9) (97.7, 100) (95.1, 100)   (86.7, 98.5) (78.4, 94.4)   (80.1, 95.3)
Booster Month 12
Primary strain 162/164; 98.8 170/170; 100 75/75; 100 73/74; 98.6 74/75; 98.7
   (95.7, 99.9) (97.9, 100) (95.2, 100) (92.7, 100)   (92.8, 100)
Booster strain 135/164; 82.3 170/170; 100 72/75; 96.0 69/74; 93.2 73/75; 97.3
   (75.6, 87.8) (97.9, 100) (88.8, 99.2) (84.9, 97.8)   (90.7, 99.7)
Booster Month 36
Primary strain 58/75; 77.3 55/75; 73.3 74/74; 100 74/75; 98.7
     (66.2, 86.2) (61.9, 82.9) (95.1, 100) (92.8, 100)
Booster strain 17/75; 22.7 19/75; 25.3 75/75; 100 74/75; 98.7
     (13.8, 33.8) (16.0, 36.7) (95.2, 100) (92.8, 100)
  Month 6 6 + 21 days 12 12 + 21 24 36 36 + 21 48
GMT value (95% CI) Booster at Month 6
Primary strain 169.9; 1566.3; 159.4; 74.0; 62.0; 71.4;
(152.3, 189.4) (1342.1, 1827.9) (128.1, 198.2)   (62.5, 87.5) (52.1, 73.7)   (61.8, 82.5)
Booster strain 179.7; 2702.0; 134.0; 66.3; 55.4; 54.5;
(161.8, 199.7) (2270.4, 3215.6) (107.4, 167.3)   (54.5, 80.8) (45.5, 67.6)   (45.8, 64.7)
Booster Month 12
Primary strain 204.1; 2734.9; 164.9; 121.1; 117.4;
   (179.9, 231.6) (2334.4, 3204.2) (125.7, 216.2) (91.7, 159.9)   (92.7, 148.6)
Booster strain 58.5; 2363.2; 148.9; 106.9; 103.4;
   (50.8, 67.3) (2037.5, 2740.9) (111.8, 198.3) (81.6, 140.0)   (79.5, 134.4)
Booster Month 36
Primary strain 33.3; 31.8; 1373.4; 429.0;
     (28.8, 38.4) (27.3, 36.9) (1023.7, 1842.6) (322.2, 571.2)
Booster strain 16.7; 17.3; 1154.3; 320.4;
     (15.4, 18.1) (15.8, 19.0) (847.8 1571.4) (243.7, 421.4)
  Month 6 6 + 21 days 12 12 + 21 24 36 36 + 21 48
Booster SCR n/N;% (95% CI) Booster at Month 6
Primary strain 121/163; 74.2 7/75; 9.3 1/75; 1.3 0/75; 0.0 0/75; 0.0
  (66.8, 80.8) (3.8, 18.3)   (0.0, 7.2) (0.0, 4.8)   (0.0, 4.8)
Booster strain 144/162; 88.9 4/74; 5.4 0/74; 0.0 0/75; 0.0 1/75; 1.3
  (83.0, 93.3) (1.5, 13.3)   (0.0, 4.9) (0.0, 4.8)   (0.0, 7.2)
Booster Month 12
Primary strain 141/164; 86.0 7/75; 9.3 5/74; 6.8 2/75; 2.7
    (79.7, 90.9) (3.8, 18.3) (2.2, 15.1)   (0.3, 9.3)
Booster strain 159/164; 97.0 34/75; 45.3 27/74; 36.5 27/75; 36.0
    (93.0, 99.0) (33.8, 57.3) (25.6, 48.5)   (25.2, 47.9)
Booster Month 36
Primary strain 73/74; 98.6 64/75; 85.3
       (92.7, 100) (75.3, 92.4)
Booster strain 75/75; 100 72/75; 96.0
        (95.2, 100) (88.8, 99.2)
  1. CI, confidence interval; n/N, number of subjects fulfilling definition of outcome/total number of subjects in group; GMT, geometric mean titer; Booster SCR, Booster seroconversion rate defined as percentage of subjects with pre-booster titer <1:28 and post-booster titer of ≥1:56, or pre-booster titer ≥1:28 and ≥4-fold post-booster; Primary vaccine strain, H5N1/A/Vietnam/1194/2004; heterologous booster strain H5N1/A/Indonesia/5/2005.